Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
Statin-Fibrate Combination for the Treatment of Dyslipidaemia
Author(s): Ewa Dembowski , Michael H Davidson Added: 3 years ago
Pharmacological regulation of lipid metabolism in patients with dyslipidaemia is undeniably associated with significant reductions in risk of cardiovascular (CV) morbidity and mortality. There are strong clinical trial data to support the use of lipid-lowering therapies in the settings of both primary and secondary prevention. Statins and fibrates are two classes of drug that have demonstrated… View more

Prevention & Chronic Conditions
New Perspectives on Atherogenic Dyslipidaemia and Cardiovascular Disease
Author(s): Alberto Lorenzatti , Peter P Toth Added: 3 years ago
We are witnessing an epidemic global increase in the prevalence of obesity and its clinical consequences (e.g. insulin resistance and diabetes). This epidemic has been potentiated and sustained by the widespread adoption of unhealthy lifestyles in broad swathes of the population and is characterised by a sedentary lifestyle and an imbalance between the type and characteristics of nutrition,… View more

Prevention & Chronic Conditions

MI/ACS
ECR Nicholls
Author(s): Stephen J Nicholls Added: 3 years ago
Therapeutic targeting of dyslipidaemia has been one of the major successes in cardiovascular medicine over the last three decades. On the basis of unequivocal evidence from animal models through to both population and genetic studies in humans, there is a clear association between increasing levels of LDL cholesterol (LDL-C) and incident cardiovascular risk.1 This has prompted efforts to develop… View more

Prevention & Chronic Conditions
Emerging Strategies for the Management of Atherogenic Dyslipidaemia
Author(s): Anandita Agarwala , Michael D Shapiro Added: 3 years ago
Atherogenic dyslipidaemia encompasses a broad variety of lipid phenotypes. While LDL cholesterol is a well-known risk factor for atherosclerotic cardiovascular disease (ASCVD), there are additional atherogenic lipoproteins that may be targeted to further reduce ASCVD risk. In their comprehensive review, Lorenzatti and Toth emphasise that, even when LDL cholesterol levels are optimised, ASCVD… View more

MI/ACS
APSC Consensus Recommendations on Dyslipidaemia
Author(s): Natalie Koh , Brian Ference , Stephen J Nicholls , et al Added: 2 years ago

Standards & Guidelines

Prevention & Chronic Conditions
Statin Therapy and the Assessment of Hepatoprotection in Patients with Dyslipidaemia
Author(s): Marinela Beznă , Gabriela Mitoaica , Lorena Ungureanu , et al Added: 12 months ago

Prevention & Chronic Conditions
Author(s): Antonio J Vallejo-Vaz Added: 3 years ago
Elevated LDL cholesterol (LDL-C) plays a major role in the development of atherosclerotic cardiovascular disease (ASCVD). Multiple studies and meta-analyses, including randomised controlled trials, prospective cohort studies and Mendelian randomisation studies, have consistently shown an association between LDL-C and ASCVD risk that is proportional to the magnitude and duration of exposure to… View more

Prevention & Chronic Conditions
Dyslipidaemia in the Real World
Author(s): Ricardo Lopez Santi , Felipe Martínez , Adrian Baranchuk , et al Added: 2 years ago

Prevention & Chronic Conditions
Job title: Professor Cardiology, Haceteppe University, Ankara, Turkey
S. Lale Tokgözoglu is Professor of Cardiology at Hacettepe University, Ankara, Turkey. She is currently the President of the European Atherosclerosis Society and Deputy Editor of the European Heart Journal. She chaired the ‘Atherosclerosis and Vascular Biology Working Group of the European Society of Cardiology’ between 2008 and 2010. Professor Tokgözoglu has served on the Board of the Turkish… View more
Research Area(s) / Expertise:
Dr Farnier is a Doctor of Medicine, a researcher and a teacher. His interests include dyslipidaemia, particularly its genetic aspects. He has conducted extensive research into type 2 diabetes and the development of new lipid-lowering drugs. View more